NC
CMPX icon

nVerses Capital’s Compass Therapeutics CMPX Stock Holding History

nVerses Capital’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.1K Buy
+23,330
New +$68.9K 0.08% 276

Other funds holding CMPX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

nVerses Capital's CMPX Position: Q2 2026 in Review

nVerses Capital opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 23,330 shares worth $51.1K. The stake represents 0.08% of the portfolio and ranks #276 among its holdings.

141 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • nVerses Capital held 23,330 shares of Compass Therapeutics worth $51.1K as of Q2 2026.
  • Compass Therapeutics was a new nVerses Capital position in Q2 2026.
  • Compass Therapeutics made up 0.08% of nVerses Capital's portfolio in Q2 2026, its #276 holding.
  • 141 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.